经济观察网 天演药业公布了2026年的业务进展及年度目标，包括多项临床数据公布与研发计划。 截至2025年12月31日，公司现金及现金等价物为7,450万美元（未经审计），预计可支持运营至2027年 底，为上述计划提供资金保障。 以上事件均基于公司公开披露的计划，具体时间及结果需以实际公告为准。 产品研发进展 患者入组完成：预计完成muzastotug随机2期剂量优化研究的患者入组，该研究旨在为3期临床试验确定 最优给药方案。 业务拓展：公司表示将持续推进合作与授权协议，包括与赛诺菲、Third Arc Bio等合作伙伴的项目进 展。 财务状况 近期事件 2026年第一季度：计划公布muzastotug（ADG126）联合帕博利珠单抗治疗三线及以上微卫星稳定型结 直肠癌（MSS CRC）患者的1b/2期更新研究数据，包括10 mg/kg剂量组（41例患者）和20 mg/kg剂量组 （26例患者）的结果。 同期：将分享与罗氏合作的临床研究结果，评估muzastotug联合阿替利珠单抗及贝伐珠单抗用于肝细胞 癌（HCC）一线治疗的疗效与安全性。 新增数据披露：公布muzastotug联合帕博利珠单抗及标准治疗（呋 ...

Core Viewpoint - The recent stock price fluctuations of Tianyan Pharmaceutical (ADAG.OQ) are influenced by technical corrections, clinical data expectations, partnership developments, and overall market sentiment [1] Stock Price Trends - Prior to the drop on February 12, the stock had increased by 17.32% over the previous seven trading days, with a single-day increase of 11.61% on February 10. The significant short-term gains likely prompted profit-taking by some investors, resulting in a 6.45% decline on February 12. However, the stock rebounded by 10.88% on February 13, indicating notable market sentiment volatility [2] Product Development Progress - The development of the company's core product, muzastotug (ADG126), is under market scrutiny. According to a business update released on January 26, 2026, Tianyan Pharmaceutical plans to announce clinical data updates for the drug in combination with pembrolizumab for colorectal cancer in the first quarter of 2026. Additionally, the partnership with Sanofi, involving a strategic investment of up to $25 million, and the FDA's grant of fast track designation may influence investor expectations regarding long-term value [3] Financial Status - As of December 31, 2025, the company reported unaudited cash and cash equivalents of $74.5 million, which is expected to support operations until the end of 2027. This financial stability alleviates market concerns regarding short-term funding pressures [4] Market Environment - On February 12, the Nasdaq index fell by 1.91%, while the biotechnology sector saw a slight increase of 0.78%. However, overall market risk aversion may amplify individual stock volatility. Following a market stabilization on February 13, the biotechnology sector rebounded by 1.86%, contributing to the recovery of Tianyan Pharmaceutical's stock price [5]